tetano
Editor, Senior Moderator
TH Open
. 2022 Nov 18;6(4):e408-e420.
doi: 10.1055/a-1937-9692. eCollection 2022 Oct.
Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records
Alex C Spyropoulos[SUP] 1 2 3 [/SUP], James M Crawford[SUP] 2 3 [/SUP], Yen-Wen Cindy Chen[SUP] 4 [/SUP], Veronica Ashton[SUP] 4 [/SUP], Alicia K Campbell[SUP] 4 [/SUP], Dejan Milentijevic[SUP] 4 [/SUP], W Frank Peacock[SUP] 5 [/SUP]
Affiliations
Abstract
Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some patients experience cardiovascular complications, including thromboembolic events and death. Data are needed to better inform prevention and treatment of these events. This analysis was designed to describe patient characteristics, medication use, thromboembolic events, and all-cause mortality in hospitalized COVID-19 patients in the United States. Methods This retrospective, observational cohort study identified adults hospitalized with COVID-19 (January 21, 2020-January 07, 2021) in the deidentified Optum COVID-19 Electronic Health Records dataset. Thromboembolic events and all-cause mortality were collected at any time during the variable follow-up period (up to 50 weeks). Results Of 181,995 COVID-19 patients who met eligibility criteria, 40,524 (22.3%) were hospitalized with COVID-19. Hospitalized patients had a mean age of 63 years and a Quan-Charlson comorbidity index of 1.3. Anticoagulants were used in 89.2% of patients during hospitalization and in 18.7% of postdischarge patients. Of hospitalized patients, 17.6% had a thromboembolic event during the entire follow-up period (mean time to the first event of 15 days), of whom 13.4% had an event during hospitalization; of discharged patients, 4.3% had a thromboembolic event (mean time from discharge to event of 43 days). Death during the follow-up period was reported in 15.0% of patients. Conclusions In this large, observational cohort study, patients hospitalized with COVID-19 had high rates of thromboembolic events during hospitalization and in the postdischarge period; mortality was also high in this population. Anticoagulant use was common during hospitalization. These findings support further studies to optimize in-hospital and extended prophylaxis for hospitalized COVID-19 patients.
Keywords: COVID-19; anticoagulants; hospitalization; risk factors; thromboembolism.
. 2022 Nov 18;6(4):e408-e420.
doi: 10.1055/a-1937-9692. eCollection 2022 Oct.
Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records
Alex C Spyropoulos[SUP] 1 2 3 [/SUP], James M Crawford[SUP] 2 3 [/SUP], Yen-Wen Cindy Chen[SUP] 4 [/SUP], Veronica Ashton[SUP] 4 [/SUP], Alicia K Campbell[SUP] 4 [/SUP], Dejan Milentijevic[SUP] 4 [/SUP], W Frank Peacock[SUP] 5 [/SUP]
Affiliations
- PMID: 36452205
- PMCID: PMC9674436
- DOI: 10.1055/a-1937-9692
Abstract
Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some patients experience cardiovascular complications, including thromboembolic events and death. Data are needed to better inform prevention and treatment of these events. This analysis was designed to describe patient characteristics, medication use, thromboembolic events, and all-cause mortality in hospitalized COVID-19 patients in the United States. Methods This retrospective, observational cohort study identified adults hospitalized with COVID-19 (January 21, 2020-January 07, 2021) in the deidentified Optum COVID-19 Electronic Health Records dataset. Thromboembolic events and all-cause mortality were collected at any time during the variable follow-up period (up to 50 weeks). Results Of 181,995 COVID-19 patients who met eligibility criteria, 40,524 (22.3%) were hospitalized with COVID-19. Hospitalized patients had a mean age of 63 years and a Quan-Charlson comorbidity index of 1.3. Anticoagulants were used in 89.2% of patients during hospitalization and in 18.7% of postdischarge patients. Of hospitalized patients, 17.6% had a thromboembolic event during the entire follow-up period (mean time to the first event of 15 days), of whom 13.4% had an event during hospitalization; of discharged patients, 4.3% had a thromboembolic event (mean time from discharge to event of 43 days). Death during the follow-up period was reported in 15.0% of patients. Conclusions In this large, observational cohort study, patients hospitalized with COVID-19 had high rates of thromboembolic events during hospitalization and in the postdischarge period; mortality was also high in this population. Anticoagulant use was common during hospitalization. These findings support further studies to optimize in-hospital and extended prophylaxis for hospitalized COVID-19 patients.
Keywords: COVID-19; anticoagulants; hospitalization; risk factors; thromboembolism.